Which HPV strains should be covered in a new treatment?
In the early 1980’s scientist Harald zur Hausen demonstrated by a southern blot analysis the presence of Human papillomavirus types HPV16 and HPV18 in cervical cancer biopsies as well as several cervical cancer-derived cell lines in the first immortalized human cells grown in culture. Now HPV is recognized as a human cancer virus responsible for causing virtually all cases of cervical cancer in women. According to the World Health Organization, “Worldwide, cervical cancer is the fourth most frequent cancer in women with an estimated 570,000 new cases in 2018 representing 7.5% of all female cancer deaths.”
According to Sarid and Gao, “high-risk HPVs 16, 18, 31 and 45 account for up to 80% of cervical cancer”, as a healthcare professional I propose a new treatment on these four high risks HPVs in efforts to prevent and limit the rising cases of HPV and cervical cancer.
There is an existing HPV vaccine against some high risk HPV strains including HPV16 and HPV18 which could be used to our advantage, basically updating the vaccine and making it stronger to fight against even more strains and ultimately eradicating the transmission of HPV. Since HPV is a sexually transmitted infection I would recommend administering to the public before the stage of puberty. I also think there should be accessible information for the general public explaining HPV and the vaccine while also underlining the importance of eradicating the carcinogenic causing virus.
Sarid, R., & Gao, S.-J. (2011). Viruses and human cancer: From detection to causality. Cancer Letters, 305(2), 218–227. https://doi.org/10.1016/j.canlet.2010.09.011
World Health Organization. (n.d.). Human papillomavirus (HPV) and cervical cancer. World Health Organization. Retrieved October 10, 2021, from https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer.